Subscribe to receive this FREE daily commentary directly in your email
Biotech Stocks May Have Finally Been Unleashed
Michael Kramer and the Clients of Mott Capital Own CELG
[widget id=”text-19″]
Stocks continued to move higher, led by the Biotech’s, which were up by about 3 percent. There’s something we haven’t said in a long time. The highly anticipated speech regarding drug prices by the President didn’t seem to be as bad as many had feared. Increasing competition, deregulation, cutting out the middlemen, is at the core of the proposals, based on my interpretation.
The drug pricing overhang had plagued this sector since September 2015, when Hillary Clinton made it a political point in the race for President. If this is the worst of it, I think the group might have much further to rise. Companies like Celgene, Gilead, Biogen, and Amgen are all trading at some of their lowest earnings multiples in years. Albeit for good reasons in some cases, but some of the valuations seem excessively low.
The details aren’t fully known yet, and what ends up getting put into law may be very different. But just knowing the blueprint for how they plan to tackle drug pricing might unleash the sector from the shackles of the past three years.
I think the group is likely heading higher.
[widget id=”text-22″]
S&P 500
The S&P 500 continues to rally, and finished near the highs at 2727, up about 2.5 percent. The setup continues to look strong.
[widget id=”text-16″]
Amazon
Technology stocks continue to look strong as well and so do consumer stocks, even though Amazon still didn’t break out. $1620 is proving, for now, to be tough for Amazon. Now that I’m calling for it to rise, it will probably go down! Ugh. We shall see.
[widget id=”wordads_sidebar_widget-41″]
Nvidia
I’m surprised Nvidia was down today. But I also do not think today’s price actions mean the stock is going lower. Shares held firmly above support around $253. The results were stunning, and this probably keeps working higher.
[widget id=”text-28″]
Amgen
Amgen shares continue to look strong as well, with a well-defined double bottom, and what looks like a solid path towards $178 to $180 range.
Unlock Deeper Insights with Exclusive Member-Only Video Content on The Market Chronicles YouTube Channel – Just $34.99/Month
[youtube-feed feed=7][widget id=”wordads_sidebar_widget-41″]
Gilead
Gilead also looks as if it could see a rise to about $72.
[widget id=”text-22″]
Biogen
Biogen also looks like it is on the cusp of a big breakout.
That is going to be it for today.
Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets
Just $200 Per Year – Get Your Free 2 Week Trial
Recent Videos:
The Setup In Stocks Continues To Improve
A Rise Back To 2,800 On The S&P Is In The Works
Why It Is Time To Dump Starbucks, Plus A Look At ACAD
It’s Back! Apple Investors Are Worried Once Again
A Review Of Netflix, IBM And Earnings Outlook
Free Articles Written By Mike:
Broadcom Traders Bet on 12% Rebound
Costco May Plunge 11% as Growth Slows
Square’s Stock Seen Rising 12% By June
Disney’s Stock Is Poised to Rise By 10%
Gilead May Rebound By 12% Short Term
Tesla Stock May Break Out, Fueling a 10% Increase
Alphabet’s Battered Stock May Jump 7% Short Term
3 Overvalued Stocks That May Fall Sharply
3 Tech Stocks Nearing a Breakout
Roku’s Stock Faces Huge 17% Price Swing on Results
Nvidia’s Stock Poised For Big 8% Jump On Earnings
Amazon Traders Bet Stock Will Rise 12% Further
Microsoft Bulls Look for More Big Gains
Why S&P 500 Stocks May Rebound 6% Short Term
Chipmakers May Soon Rebound to New Highs
Biotech Stocks Set to Breakout
Join our 2,630 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe
Photo credit via Flickr
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.
© 2018 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.
Tags: #biotech #amgen #gilead #biogen #technology #amazon #sp500
Subscribe to receive this FREE daily commentary directly in your email
This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.